Godavari Biorefineries Reports Q1 FY26 Turnaround with Positive EBITDA and Strategic Expansion Plans
Godavari Biorefineries Limited (GBL) reported improved Q1 FY26 results with revenue at INR 533.20 crores, up from INR 522.50 crores in Q1 FY25. The company achieved a positive EBITDA of INR 6.50 crores, reversing previous losses. Bio-based chemical segment EBITDA increased by 43%. GBL is expanding its ethanol production with a new 200 KLD grain-based distillery. The company projects 3x EBITDA growth from FY25 to FY29, driven by bio-based specialty chemicals and ethanol capacity expansion. GBL also made progress in drug discovery, receiving European and Chinese patents for anti-cancer compounds.

*this image is generated using AI for illustrative purposes only.
Godavari Biorefineries Limited (GBL) has reported a significant turnaround in its financial performance for the first quarter of fiscal year 2026, marking a positive shift in its strategic direction towards bio-based specialty chemicals and renewable energy.
Financial Highlights
- Revenue from operations stood at INR 533.20 crores, up from INR 522.50 crores in Q1 FY25.
- Achieved a positive EBITDA of INR 6.50 crores, compared to a loss in the same quarter last year, representing an improvement of INR 16.00 crores.
- Gross margin expanded by 512 basis points year-on-year to 19%.
- Interest costs decreased by 22% year-on-year to INR 15.00 crores, attributed to debt reduction efforts.
Segment Performance
- The bio-based chemical segment registered a robust 43% increase in EBITDA, underscoring the growing demand for green chemistry solutions.
- The ethanol segment benefited from the restoration of the ethanol blending program, allowing for optimized production from B-heavy molasses during the off-season.
Strategic Initiatives and Future Outlook
Ethanol Expansion: GBL is progressing with the construction of a 200 kiloliters per day grain-based ethanol distillery, expected to commence commercial production by the end of calendar year 2025. This facility is projected to generate over INR 400.00 crores in revenue at current pricing levels.
Bio-based Specialty Chemicals: The company continues to focus on strengthening its bio-based specialty chemical portfolio through de-bottlenecking, process optimization, and development of high-value specialty chemicals.
Drug Discovery: GBL has made significant strides in its drug discovery initiatives:
- Received European patent validation for a novel anti-cancer molecule.
- Completed safety trials without dose-limiting toxicity.
- Secured a Chinese patent for another promising anti-cancer compound.
Financial Projections: Management projects a 3x EBITDA growth from FY25 to FY29, driven by bio-based specialty chemicals and ethanol capacity expansion.
Management Commentary
Samir Somaiya, Chairman and Managing Director, stated, "Q1 FY '26 has been a quarter of positive change for Godavari Biorefineries Limited, advancing a strategic shift towards bio-based specialty chemicals and renewable energy based on multiple feedstocks. Our performance reflects the strength of our diversified portfolio and our commitment to sustainable innovation."
The company's focus on ethanol production aligns with the Indian government's push for energy security and green energy transition. With the recent achievement of a 20% ethanol blend in petrol nationwide, and potential plans to increase this to 27%, GBL is well-positioned to capitalize on this growing market.
As Godavari Biorefineries Limited continues to execute its strategic priorities, including de-bottlenecking, specialty chemical development, and enhancing multi-feedstock ethanol capabilities, the company appears poised for sustained growth and improved profitability in the coming years.




































